Anti-PSMA [MLN591 (deJ591)]

Description:

Recombinant monoclonal antibody to PSMA. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma MLN591 (deJ591).

Clone Name:

MLN591 (deJ591)

Published Application(s):

in vivo, IP, RIA, therapeutic, WB, ELISA, FC, IF, IHC

Published Species Reactivity:

Human

UniProt Accession Number of Target Protein: Q04609

Alternative Name(s) of Target: PSM; FOLH1; FOLH; FGCP; GCPII; mGCP; NAALAD1; GIG27; Prostate specific membrane antigen; Glutamate carboxypeptidase 2; Cell growth-inhibiting gene 27 protein; Folate hydrolase 1; Folylpoly-gamma-glutamate carboxypeptidase; Glutamate carboxypeptidase II; Membrane glutamate carboxypeptidase; N-acetylated-alpha-linked acidic dipeptidase I; NAALADase I; Prostate-specific membrane antigen; Pteroylpoly-gamma-glutamate carboxypeptidase
Immunogen: The original antibody was raised by immunizing a mouse with human PMSA. The variable domain regions of mouse J591 were deimmunized by site-directed mutagenesis of putative T-cell reactive epitopes.

Specificity: This antibody binds the extracellular domain of the human PSMA. Prostate-specific membrane antigen (PSMA) is a type II integral membrane glycoprotein belonging to the M28 peptidase family. It acts as a glutamate carboxypeptidase on different alternative substrate. It is highly expressed in cancerous cells and is used as an effective diagnostic and prognostic indicator of prostate cancer.

Application Notes: This antibody is the de-immunized version of anti-PSMA antibody J591. The radiolabelled version of this antibody was used for a radioimmunoassay on PMSA (US7514078B2). This antibody has been widely used for conjugation with drug maytansinoid 1 (DM1) a microtubule depolymerising agent, through thiopentanoate linker modification method of the antibody. The resulting immunoconjugate (MLN2704) contains 3-4 DM1 molecules per antibody. The immunoconjugate is a chemotherapeutic agent which effectively penetrates xenograft tumor tissue (PMID: 15520207). A phase I trials in patients with progressive, metastatic, castration-resistant prostate cancer investigated the safety profile, pharmacokinetics, immunogenicity, and preliminary antitumor activity of MLN2704. It was observed that the toxicity profile differs substantially from other PSMA-targeted therapies and is more typical of systemic chemotherapy, with nausea, fatigue, and diarrhea being the most commonly encountered adverse effects (PMID: 18362364). In the second study, using the yttrium-90-labeled deJ591-DOTA conjugate, with 61 progressive metastatic CRPC patients, most commonly encountered toxicities were also nausea, fatigue, and schedule-dependent neurotoxicity. Dose limiting toxicity was determined to be grade 3 transaminitis (PMID: 15173215). Another phase 1/2 study evaluated the dose-limiting toxicity and maximum tolerated dose of MLN2704. It reported that MLN2704 has limited activity in metastatic CRPC. Disulfide linker lability and rapid deconjugation lead to neurotoxicity and a narrow therapeutic window (PMID: 27765518). The DOTA labelled antibody was used for immunohistochemistry on human tissue. Here it showed specificity for prostate tissue. This antibody was used for an in vivo biodistribution experiment on nude mice. The uptake of this antibody by tumours was significantly higher than the control experiment. Furthermore the radiolabelled version of this antibody was used to treat mice with PMSA positive tumours. The labelled antibody was able to reduce mean tumour size by 80%-97%. The radiolabelled antibody was also tested in vivo in human. Here it showed that is targeted well to prostate cancer sites and it showed no toxic side effects in the patients. This antibody was also used for phase I and phase II trials where it showed some positive results (US7514078B2).

Antibody first published in: Henry et al. A prostate-specific membrane antigen-targeted monoclonal antibody-chemotherapeutic conjugate designed for the treatment of prostate cancer. Cancer Res. 2004 Nov 1;64(21):7995-8001. PMID:15520207
Note on publication: Describes the generation of an antibody-drug immunoconjugate which can be used for treatment of prostate cancer.

Privacy Overview

Customize your consent preferences for Cookie Categories and advertising tracking preferences for Purposes & Features and Vendors below. You can give granular consent for each and . Most vendors require explicit consent for personal data processing, while some rely on legitimate interest. However, you have the right to object to their use of legitimate interest.

Necessary

Always Enabled

Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.

Cookie	Duration	Description
ASP.NET_SessionId	session	Issued by Microsoft's ASP.NET Application, this cookie stores session data during a user's website visit.
cookielawinfo-checkbox-advertisement	1 year	Set by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Analytics

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.

Cookie	Duration	Description
_dc_gtm_UA-49047364-1	1 minute	No description
_ga	2 years	The _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_gcl_au	3 months	Provided by Google Tag Manager to experiment advertisement efficiency of websites using their services.
_gid	1 day	Installed by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.
ai_session	30 minutes	This is a unique anonymous session identifier cookie set by Microsoft Application Insights software to gather statistical usage and telemetry data for apps built on the Azure cloud platform.
ai_user	1 year	A unique user identifier cookie, set by Microsoft Application Insights software, that enables counting of the number of users accessing the application over time.

Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.

Cookie	Duration	Description
_uetsid	1 day	Bing Ads sets this cookie to engage with a user that has previously visited the website.
_uetvid	1 year 24 days	Bing Ads sets this cookie to engage with a user that has previously visited the website.
MUID	1 year 24 days	Bing sets this cookie to recognize unique web browsers visiting Microsoft sites. This cookie is used for advertising, site analytics, and other operations.
test_cookie	15 minutes	The test_cookie is set by doubleclick.net and is used to determine if the user's browser supports cookies.

Third Party Vendors

Google Ad Tech Providers